



Date: 15 February 2017

Sydney, Australia

UPCOMING EVENTS

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4,
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

Noxopharm is pleased to inform its shareholders and the market generally of the following opportunities for the Company to provide an update on its progress since listing on 9th August 2016.

Tuesday February 21, 2017 12.30pm- 2.00pm

Noxopharm CEO, Dr Graham Kelly, is invited to present at ASX and FNN The CEO Sessions

ASX Auditorium, 18 Bridge Street, Sydney 2000

For registrations, please visit: <http://www.asx.com.au/seminars/ceo-sessions/>

Tuesday May 30, 2017 11am -1.00pm

Noxopharm Limited Mid-year Shareholder Briefing: Melbourne

Radisson on Flagstaff Gardens Hotel, 380 William St, Melbourne

Friday June 2, 2017 1pm - 3 pm

Noxopharm Limited Mid-year Shareholder Briefing: Sydney

Sofitel Sydney Wentworth, 61-101 Phillip St, Sydney

**For enquiries, please contact Prue Kelly: info@noxopharm.com
or +61 (2) -9144 2223**

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells regulated by sphingosine-1-phosphate that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly
E: info@noxopharm.com T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.